Last Updated : May 15, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Olmetec | Olmesartan medoxomil | Hypertension | List in a similar manner to other drugs in class | Complete | ||
| Olmetec Plus | Olmesartan medoxomil + hydrochlorothiazide | Hypertension | List in a similar manner to other drugs in class | Complete | ||
| Olumiant | baricitinib | Alopecia areata, severe | Active | |||
| Olumiant | baricitinib | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete | ||
| Omnaris | Ciclesonide nasal spray | Allergic Rhinitis (seasonal and perennial) | Do not list | Complete | ||
| Omnitrope | Somatropin (rDNA origin) | Growth hormone deficiency in children and adults | N/A | Complete | ||
| Omvoh | mirikizumab | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Onbrez | Indacaterol | Chronic obstructive pulmonary disease | List in a similar manner | Complete | ||
| Oncaspar | Pegaspargase | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Ondexxya | andexanet alfa | Reversal of FXa inhibitor anticoagulant effects | Do not reimburse | Complete |
Last Updated : May 15, 2024